Precigen (NASDAQ:PGEN) Share Price Passes Below Two Hundred Day Moving Average – What’s Next?

Precigen, Inc. (NASDAQ:PGEN) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.01 and traded as low as $3.63. Precigen shares last traded at $3.81, with a volume of 7,885,584 shares traded.

Wall Street Analyst Weigh In

PGEN has been the subject of several research reports. Zacks Research cut Precigen from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 22nd. HC Wainwright raised their price objective on shares of Precigen from $8.50 to $9.00 and gave the company a “buy” rating in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research note on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Precigen from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Precigen currently has a consensus rating of “Hold” and an average price target of $8.50.

Precigen Stock Performance

The firm’s fifty day simple moving average is $4.45 and its 200 day simple moving average is $4.01. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -2.74 and a beta of 1.07. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.04 and a quick ratio of 3.95.

Insider Transactions at Precigen

In other news, Director Randal J. Kirk sold 1,900,036 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $4.18, for a total value of $7,942,150.48. Following the completion of the sale, the director owned 341,189 shares in the company, valued at $1,426,170.02. This represents a 84.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 47.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Investment Insight Wealth Management LLC purchased a new stake in Precigen in the 4th quarter worth about $443,000. Invesco Ltd. grew its stake in Precigen by 250.8% during the 4th quarter. Invesco Ltd. now owns 373,782 shares of the biotechnology company’s stock valued at $1,562,000 after acquiring an additional 267,223 shares in the last quarter. NewEdge Advisors LLC acquired a new position in shares of Precigen in the 4th quarter valued at about $45,000. XTX Topco Ltd lifted its position in shares of Precigen by 25.2% in the fourth quarter. XTX Topco Ltd now owns 49,668 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 10,005 shares in the last quarter. Finally, VARCOV Co. purchased a new stake in shares of Precigen in the fourth quarter worth approximately $224,000. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.